Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated Share Price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 12:30:33 01/06/2024 am IST 		5-day change 1st Jan Change
451.3 USD +1.87% Intraday chart for Vertex Pharmaceuticals Incorporated -1.35% +10.79%
01:40pm BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
10:09am Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT

Financials

Sales 2024 * 1.08TCr 90TCr Sales 2025 * 1.17TCr 97TCr Capitalization 11TCr 9,53700Cr
Net income 2024 * 398Cr 33TCr Net income 2025 * 444.1Cr 37TCr EV / Sales 2024 * 9.33 x
Net cash position 2024 * 1.4TCr 1,16600Cr Net cash position 2025 * 1.86TCr 1,55100Cr EV / Sales 2025 * 8.2 x
P/E ratio 2024 *
29.2 x
P/E ratio 2025 *
26.1 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.89%
More Fundamentals * Assessed data

Chart Vertex Pharmaceuticals Incorporated

Dynamic Chart

Latest news about Vertex Pharmaceuticals Incorporated

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director CI
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497 MT
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone MT
FOMO is Back Our Logo
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
More news

Latest transcript on Vertex Pharmaceuticals Incorporated

Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
More transcripts

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
More recommendations

Press releases Vertex Pharmaceuticals Incorporated

Vertex to Participate in Upcoming June Investor Conferences BU
Jennifer Schneider Elected to Vertex Board of Directors BU
Vertex: Q1 Earnings Snapshot AQ
Vertex Reports First Quarter 2024 Financial Results BU
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older BU
More press releases

News in other languages on Vertex Pharmaceuticals Incorporated

ETF de la semana: Las materias primas siguen teniendo potencial
Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
ETF de la semana: Los “utilities” desempeñan un papel en la aparición del AII
Compañías que se deben tener muy en cuenta por técnico este lunes en Wall Street
Valores destacados al cierre del mercado norteamericano
More news

Quotes and Performance

1 day+1.87%
1 week-1.35%
Current month+14.76%
1 month+12.10%
3 months+6.31%
6 months+28.37%
Current year+10.79%
More quotes

Highs and lows

1 week
435.57
Extreme 435.57
454.79
1 month
394.03
Extreme 394.0323
457.66
Current year
391.01
Extreme 391.01
457.66
1 year
320.01
Extreme 320.01
457.66
3 years
176.36
Extreme 176.36
457.66
5 years
165.23
Extreme 165.23
457.66
10 years
63.68
Extreme 63.68
457.66
More quotes

Managers and Directors - Vertex Pharmaceuticals Incorporated

Managers TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 01/17/01
Jeffrey Leiden CHM
 Chairman 68 08/09/08
Charles Wagner DFI
 Director of Finance/CFO 56 10/19/10
Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 08/17/08
Jeffrey Leiden CHM
 Chairman 68 08/09/08
Bruce Sachs BRD
 Director/Board Member 64 01/98/01
More insiders

ETFs positioned on Vertex Pharmaceuticals Incorporated

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
7.67% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
7.08% 0 M€ 0.00% -
More ETFs positioned on Vertex Pharmaceuticals Incorporated

Quotes

Date Price Change Volume
01/24/01 450.8 +1.74% 600 215
30/24/30 443 +0.44% 975,367
29/24/29 441.1 -1.29% 967,463
28/24/28 446.9 -2.20% 1,379,608
24/24/24 457 +1.36% 1,050,952

Delayed Quote Nasdaq, May 01, 2024 at 12:15 am IST

More quotes

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
Biotechnology & Medical Research
Calendar
05/06/2024 - William Blair Growth Stock Conference
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
443 USD
Average target price
462.8 USD
Spread / Average Target
+4.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+10.79% 11TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.75% 10TCr
BIONTECH SE Stock BioNTech SE
-4.83% 2.38TCr
ARGENX SE Stock argenx SE
-0.82% 2.17TCr
GENMAB A/S Stock Genmab A/S
-10.12% 1.81TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 1.63TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.34% 1.61TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.00% 1.38TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.72% 1.18TCr
INSMED INCORPORATED Stock Insmed Incorporated
+75.07% 918.67Cr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock